[Autologous transplantation of peripheral blood stem cells in malignant lymphomas].
The administration of high dose chemotherapy and or radiotherapy with autologous hematopoietic rescue has become a treatment modality with increasing number of indications in a variety of malignant conditions. Improvements in the conditioning regimens and supportive measures used, as well as a more refined patient selection based on prognostic factors, have resulted in progressively better results. The availability of precursor cells from peripheral blood has allowed a faster restoration of hematopoiesis, decreasing the period and intensity of myelosuppression. The following revision gives an updated image of the accumulated experience with this mode of support in malignant lymphomas.
Sánchez Luceros
A
A
Unidad de Trasplante de Médula Osea de Clínica Independencia, Hospital Privado de Oncología, Munro, Buenos Aires.
Koziner
B
B
D000971:Antineoplastic Combined Chemotherapy Protocols; D016026:Bone Marrow Transplantation / Q000401:mortality; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007902:Length of Stay; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D014182:Transplantation, Autologous
Trasplante autólogo de células precursoras de sangre periférica en linfomas malignos.